Tag: IBD research

You Bring the Spoons, They Bring the Science: How ImYoo is Working to Change the Narrative of IBD 

Leave a comment

This article was sponsored by ImYoo. All thoughts and opinions shared are my own.

Precision medicine is a common term we hear when it comes to treating IBD now and into the future. But have you heard about citizen science as it relates to IBD? Citizen science gives everyone a chance to play an active role in research. Whether that’s coming up with research ideas or taking part in the experiments themselves, citizen science makes it possible for you to have a direct impact. A company spun out of Caltech is taking citizen science to a whole new level. ImYoo is debugging the human immune system by using at-home blood collection kits and single RNA sequencing to discover insights about autoimmune diseases.

Tatyana Dobreva and her co-founder, David Brown, worked at NASA prior to switching gears from space to focus on biotech.

“The COVID-19 pandemic accelerated the process and highlighted for us what was missing. Since the pandemic, people are paying more attention to their immune systems. Immunology is still as much a mystery as outer space, so that was the next frontier we wanted to get involved in. We feel that the best way to take on that challenge is by building a database across time, for every individual – that is what can make personalized medicine possible and that is why we’re so focused on making this research accessible.”

Since IBD presents uniquely in each person and changes over time, it’s a rollercoaster journey of highs to lows, flares to remission. With all the twists, turns, and complexities that ulcerative colitis and Crohn’s create for each of us in the patient community, following a roadmap can seem impossible.

“Precision medicine tries to apply scientific tools to take out some of this guesswork. A lot of those tools look at the genetic material you inherited from your parents. We’re adding another tool to that kit by looking at the expression of those genes. For IBD, we want to figure out which genes and cells are acting up during a flare,” said Tatyana.

By answering these key questions, clinicians have told Tatyana that it will help gastroenterologists make more informed decisions when it comes to treating and managing IBD and patients can feel more empowered every step of the way. While making the decision to start a biologic can be overwhelming for patients, precision medicine is a way to have powerful data to support the choice to move forward with that treatment plan.

Tracking the immune system over time 

ImYoo’s focus is tracking a person’s immune system over time. Researchers do this by looking at RNA expression. Tatyana shared a fantastic analogy with me. She said that DNA is like the menu you get at a restaurant, RNA is your order, and proteins are your final meal.

“There are a lot of companies that look at your blueprint, or in this case your menu – all the possibilities. Our team at ImYoo looks at your cells’ orders over time. That way we can capture how the different immune cells in your blood are changing,” said Tatyana. 

IBD flareups are of specific interest to both clinicians and patients. Even after living with Crohn’s disease for more than 17 years, the unpredictability of the disease is still one of my main struggles. The looming thoughts of a flare are always with you.

“There is not much literature on what happens in the immune system during a flare, and we think there are a lot of powerful biomarkers that could be discovered if IBD patients could track themselves during flares and when they feel “normal.” Our IBD study will ask IBD warriors to sample themselves both during and outside of flares,” said Tatyana.

ImYoo built a solid foundation for studying autoimmunity because researchers were able to build a database of “normal” immune systems.

“Being the first to do this for single-cell data means we can provide a helpful reference to enable more single-cell studies for the future. By having a large database of “healthy” immune systems, we can provide more context as to what having a flare means with respect to dysfunctional immune systems.”

How IBD Patients Can Participate

ImYoo’s IBD study was inspired by conversations researchers had across Reddit and in a Facebook group. Patients in the community offered invaluable insights about what to research.

Emily Harari works as a liaison between the scientific team at ImYoo and the patient community. She says if a person demonstrates interest in participating in the study, a screening process will take place to determine eligibility. 

If you qualify, you are enrolled under an ethics-approved study protocol and sent a kit that includes a virtually painless capillary blood self-collection device called TAP II. The device allows you to participate in immune studies in the comfort of your home and send capillary blood samples directly to the ImYoo lab. The TAP II is placed on the upper arm and sticks with the help of a gentle adhesive, it barely penetrates the inner layer of your skin and feels like a suction cup.

“For the IBD study, we ask you to collect a few samples when you’re feeling well and a few samples when you’re flaring. The TAP II device is virtually painless and takes just a couple minutes to use. You’ll mail us the tube of your sample with the packaging we provide. After several weeks we’ll report updates from the lab and several weeks after that we’ll release our study’s findings to the community. Since the community is crowdsourcing the study for us, the least we can do is share what we discover. For example, we may find a new gene or an immune cell marker that helps your doctor better treat your flares,” said Emily.

The Power of Crowdsourcing 

The best part about a crowdsourced study is that anyone can make a difference. By visiting the ImYoo crowdsourcing page and selecting “Participate in this Study!” you are making a powerful impact. The more people with IBD who join, the more attention we can attract for crowdfunding. 

“If you’re eligible for the IBD study, we’ll reach out after we’ve hit our crowdfunding goal. To help us reach our goal, you can express an interest to participate or pitch in a donation to one of our Champions’ campaigns. There’s a network effect we’re going for, one person tapping into their community can open so many doors.”

If you’ve ever been told your labs or scopes look normal or there’s nothing more to do when you’re suffering through IBD, it’s simply not true. Everyone is on their own health journey and deserves a chance to take control of it. 

“That’s why ImYoo is excited to put innovative science in peoples’ hands. This research isn’t possible without the IBD community, which is why we invite IBD Warriors to pitch in however they can – skip a coffee and donate $5, express interest to participate, or simply share to your network,” said Emily.

“Our goal is to empower the IBD community with more powerful tools. One of the biggest questions we hear from IBD folks is, “Am I in remission yet?” You might be feeling fine and think you’re good, meanwhile your immune system could be attacking your colon,” explained Tatyana. “We hope to help people track their immune systems when they are most vulnerable.”

By enabling the IBD community to crowdsource our own studies, the power is in our hands. ImYoo wants to explain their research findings every step of the way and keep people engaged, because it really is a partnership. From this IBD study, the ImYoo team wants to prove that the IBD community can make their own research happen. By studying flares, the hope is that sequencing the state of individual immune cells will uncover predictors and targets for more accessible precision medicine.

Connect with ImYoo, Follow and Participate in the Research

Website

Kernl’s Study/Donation Page

Instagram

Twitter

Facebook

Roadmap to a Cure for Crohn’s Driven to Change IBD Landscape as We Know It

Leave a comment

They call themselves “Propellers.” They’re a team of volunteers, made up of IBD patients and caregivers who created a non-profit called Propel a Cure for Crohn’s in 2016. They are laser focused on preventing and curing Crohn’s disease and, on the heels of their first research project funded at Stanford University in the world-renowned lab of Professor Mark Davis, they’re now determined to make a meaningful difference through their Roadmap to a Cure for Crohn’s effort. During this month (September 2022), they’re aiming to raise $50,000 to help get their latest project off the ground and to provide a solid foundation to bring their global team together.

This is a grassroots effort fueled by patient and parent volunteers. Patients and caregivers have an opportunity right now to directly influence a brighter future without Crohn’s! This is a peer-to-peer fundraiser—it’s not just about the monetary donations, but also sharing the message with others far and wide. Not only are international researchers involved, there are people all over the globe participating. In addition to the English-language campaign, there are also Swedish and Portuguese online campaigns running as well.

The Patient/Caregiver Perspective

Ildiko Mehes recalls what it was like when her 9-year-old daughter received her lifechanging Crohn’s disease diagnosis in 2017.

“As a parent, a serious diagnosis like Crohn’s is a huge shock, and it’s absolutely devastating and heartbreaking. Even during periods of remission, we are always on high alert and waiting for the other shoe to drop. At diagnosis, my whole world stopped, literally and figuratively. As irrational as it sounds, as a parent, you wish the rest of the world stopped with you to help you address the crisis. You wish that all of modern medicine rolled up their sleeves and urgently worked together to precisely diagnose the problem and bring her back to long-term health.”

As a caregiver, Ildiko has a unique sense of urgency and determination. She feels we need and can do better for IBD patients.

“When an otherwise healthy child, with no prior medical history, suddenly presents with IBD symptoms during a routine winter virus, you ask yourself “what caused this switch to be flipped?” Not having any answers to the underlying mechanism of disease onset or perpetuation, having a trial-and-error approach to disease management, and being forced to consider serious immunosuppressive medications with modest clinical trial benefits feels unacceptable as a parent. This is what drives me.”

As a pharmaceutical executive with more than 20 years of experience, Ildiko uses that unique skill set to go after complex and difficult goals with Propel a Cure and feels a deep sense of obligation to help our community.

“While there is excellent research ongoing in IBD, it happens in silos. It lacks global coordination and a plan. We don’t yet understand many basic things about Crohn’s. We are all just hoping for a “eureka moment” that hasn’t come over the last 100 years. We are continuously enticed with headlines of a “promising” new pathway or new drug candidate, usually in mice. And then that great idea sits there, with no progress made, a decade or more later. I know we can do better,” she said.

Natalie Muccioli Emery was diagnosed with Crohn’s disease in 2011 and she’s also a Propel a Cure Board member. She started dealing with abdominal issues 26 years ago. Being a veteran patient has provided her with perspective about how far treating and managing IBD has come and how far we still have to go.

“Propel a Cure was the first organization whose mission resonated with me. I appreciate their mission to cure Crohn’s Disease, but I even more appreciate the fact that they have laid out a plan as to what the areas of knowns and remaining unknowns are in their Roadmap to a Cure for Crohn’s project. Complex issues like Crohn’s Disease will take a collaborative and systematic approach to address, and this cause has captured that,” said Natalie.

Not only is Natalie an IBD mom, she’s also an IBD aunt!

“I believe that as an adult with IBD, the way I embody the role of a “Crohn’s Warrior” is not for myself it is for the next generation. I have “been there and done all that” with Crohn’s. But just because I did it with Crohn’s doesn’t mean the next generation should have to. I grow increasingly concerned when I see the rising rates of IBDs like Crohn’s in younger people. I believe the rising rates of Crohn’s should create a sense of urgency and a desire for a better future.”

Putting the puzzle pieces together

The Roadmap to a Cure is an ambitious project but one that is needed to drive real progress toward cures and prevention of IBDs, not just talk about “cures” in some very distant future. Ildiko says the brilliant clinicians and scientists she has gotten to know all tell her that getting to a cure will take a grassroots effort, global collaboration, and involvement of patients and caregivers.

“We at Propel a Cure are deeply committed to doing exactly that. The first step in our project is to systematize what we already know about Crohn’s today. We know a great deal, thanks to research. But when we are talking about complex fields like genetics, epigenetics, immunology, microbiology, epidemiology, multi-omics platforms and artificial intelligence, etc. there is no way any one person or group can know everything. We need a large global group of dedicated and brilliant experts to put all the puzzle pieces we already have on one table so we can begin to then put the pieces together,” she explained.

Grabbing the attention of medical professionals and researchers

Propel a Cure grabbed the attention of Dr. Bram Verstockt, MD, PhD, Department of Gastroenterology and Hepatology, University Hospitals Leuven, on social media.

“I truly like the concept of joined forces across various stakeholders, including patients and caregivers. As clinicians and scientists, we can have ideas about how to move forward based on experiences and interactions with patients on a daily basis. However, the next step really is to involve patients actively in many of these projects, as is currently the case with Propel a Cure,” said Dr. Verstockt.

The “Roadmap to a Cure” aims to bring together expertise across many different fields and niches in IBD.

“Over the past decades, a lot of scientific evidence has been generated in multiple domains of Crohn’s disease, so now it’s time to bring all that evidence together and truly connect the dots. Only by doing so, one might unravel knowns and unknowns and highlight where the remaining key gaps are, and we can define the priorities and strategies of how to fill these gaps to significantly advance the field, to improve the lives of patients with Crohn’s disease,” said Dr. Verstockt.

Where the roadmap can take us

After the initial step of putting together the state of the art, the next step is identifying gaps in our knowledge: what puzzle pieces do we still need? The third step is to develop the plan, or the Research Roadmap, to get from what we know today to developing cures and prevention strategies.

“We truly believe in a future where we can prevent and cure Crohn’s and eliminate so much patient and family suffering,” said Ildiko.

The reason this requires a grassroots effort and all of us patients and caregivers to fund it, is that otherwise the current system largely doesn’t provide incentives for new ideas or cures or global collaborative efforts of this magnitude. A recent paper discusses how the same ideas have been funded for decades, with limited progress and that we urgently need new directions.

Ildiko believes the current research incentive model is broken. “If we want true progress and cures for Crohn’s and other IBDs, we need a new collaborative model among IBD foundations/nonprofits, patients, caregivers, researchers, clinicians, and others. I believe this can become a model for other chronic and immune-mediated diseases.”

Click here to watch a video where Ildiko explains the Roadmap to a Cure project further.

Hopes for the future

“I would really like to see more key opinion leaders be brave about acknowledging the risks and limitations of current therapies, avoid putting lipstick on a pig when discussing some newer drug candidates in trials with lackluster results and the same mechanisms, dispense with biased headlines like “safe and effective” when the data is much more nuanced or unclear, and openness to “outside-the-box” ideas, like microbiome manipulation, including via diet, infectious triggers like Epstein-Barr virus in Multiple Sclerosis, vagus nerve stimulation, Fecal Microbiota Transplant (FMT), hyperbaric oxygen, etc. and also adopt routine monitoring via intestinal ultrasound for many patients,” said Ildiko.

As of now (September 12, 2022)—more than $26,609 has been raised!

“I have been overwhelmed by the response so far, as has the entire Propel team. People are really connecting with our mission. We are getting donations from so many states and countries! We have received more messages of profound thanks and hope than I can recount. This fuels us so much,” said Ildiko.

Natalie feels a wide range of emotions each time she sees a donation come in or the campaign shared across social media.

“I go from feeling hopeful, to introspective, to sad. I truly wish we did not have to do this campaign and that in 2022 we knew what the underlying cause(s) of Crohn’s are, and that safe, effective, reliable treatments were available for all Crohn’s patients. But here we are. Crohn’s is still very much part of the lives of patients and caregivers, and we need to take action to change that. I am so grateful for the outpouring of support we have received so far, but there is more work to be done!”

Propel a Cure has virtually no overhead fees or salaries, so every single dollar donated to Roadmap for a Cure goes to research.

“We are all volunteers who work out of our homes. The donations will be put towards collaborative research teams worldwide. Each team will lead a contributing area to the development of Crohn’s Disease (environment, microbiome, immune system etc.) and highlight where the gaps in knowledge remain,” said Natalie.

“The ultimate dream obviously would be to cure and if not, to significantly improve the quality of life for millions of patients worldwide,” said Dr. Verstockt.

Click here to donate to this incredible cause or to join their team.

Participating in PIANO: Why I choose to be a part of research while pregnant and beyond

Leave a comment

As an IBD mom I see it as a responsibility and an opportunity to participate in research studies while I am pregnant and as my children grow. I’m currently 20 weeks pregnant (tomorrow!) with my third baby and this time around I’m enrolled in the Pregnancy in Inflammatory Bowel Disease and Neonatal Outcomes (PIANO) study. The project was conceived, lead, and executed by Dr. Uma Mahadevan, Professor of Medicine at the University of California San Francisco in 2007.

Since the project launched, more than 1,800 women have participated in the registry. Of that number, over 900 stayed on biologics throughout their pregnancies. I’m thrilled to be a part of this initiative. If my pregnancies and children can provide clarity for a future generation of IBD moms, the extra effort on my part is more than worth it. Thanks to women before me who have been on a biologic and been a part of research while pregnant, I have peace of mind knowing that staying on my Humira is best for me and for baby.

Without studies that indicate how babies in utero respond to medication exposures we would be in the dark about what is best for mom and baby not only during pregnancy, but with breastfeeding.

“There is so much misinformation about pregnancy and IBD including being told not to conceive at all or to stop medication. This is incorrect and dangerous. PIANO was started to provide reliable data for women with IBD considering pregnancy so they and their providers can make an informed choice for themselves and their babies,” said Dr. Mahadevan. “Every pregnant woman with IBD has benefited from the generosity of PIANO moms who contributed their outcomes, good or bad, to the pool of knowledge we have. Every PIANO mom who contributes benefits not herself, but future mothers with IBD. It is an invaluable and precious gift.”

What PIANO measures

There are four main areas the PIANO study looks at:

  1. Whether the level of biologic drug transferred across the placenta to the infant by the time of birth predicts the risk of infection or other adverse outcomes
  2. Whether the achievement of developmental milestones is affected by medication exposure
  3. Whether the rates of birth defects, adverse pregnancy outcomes and complications of labor and delivery are affected by IBD medications
  4. Whether second trimester drug levels can be used to adjust drug and minimize transfer across the placenta to the baby

Since I am just now reaching the halfway point of my pregnancy, I have only had to fill out questionnaires. You are required to do so during each trimester, at the end of your pregnancy, and then at 4, 9, and 12 months post-delivery. Along with that, you can provide follow up until your child is 18, once a year. During this trimester I will also provide blood work and a fecal calprotectin. On delivery day, bloodwork will be taken from me, my baby, and my umbilical cord. Depending on my son’s blood work at delivery, I may be asked for more when he’s 3 and 6 months. If at any time I am not comfortable with him getting his blood drawn, I can always opt out. The cord blood is similar to the baby blood at birth so that is adequate. I can also choose to stop the annual questionnaire at any time.

If a woman receives the COVID-19 vaccine during pregnancy, the PIANO study is also measuring the antibody levels found in the cord blood (on the day of birth) to confirm that the benefit transfers to the baby. Breastmilk will also be measured for the transfer of protective antibody against COVID.

The Findings Thus Far

In a presentation this past fall, Dr. Mahadevan shared findings from PIANO.

“We looked at pregnancy, birth and developmental outcomes in the infants at one year, based on exposure to drug, and found no increase in negative outcomes and no reduction in developmental milestones. Biologic‑exposed infants did have some statistically increased improvement in developmental milestones compared to the unexposed group. Overall, what this study suggests is that women with inflammatory bowel disease should continue their biologics and thiopurines throughout pregnancy to maintain remission, given no evidence of harm, and evidence that  disease activity can increase miscarriage.”

The study also found that disease activity can increase preterm labor and birth, all the more reason for women to stay on their medication and not try and go med-free while pregnant.

Looking to the Future

Currently, there is no end date for the study. As long as there is funding, the project will continue. Dr. Mahadevan says with all the new medications coming down the pipeline there is a need for safety data. She says, “The infrastructure of PIANO allows us to study new medications as they come to market, even before they are approved for IBD.”

To participate in the study women must have IBD and live in the United States. Interested in learning more or getting enrolled? Email PIANO@ucsf.edu or call 415-885-3734.